Subscribe to our email list for the latest updates

RadioGelUSA
Home
The Science of RadioGel®
Press Releases
PRnT™
IDE Submission
Research Papers
RadioGel® Cancer Blog
RadioGel® T-Shirt Contest
Meet The Team
Contact Us
Vivos Inc.
IsoPet®
Subscribe
RadioGelUSA
Home
The Science of RadioGel®
Press Releases
PRnT™
IDE Submission
Research Papers
RadioGel® Cancer Blog
RadioGel® T-Shirt Contest
Meet The Team
Contact Us
Vivos Inc.
IsoPet®
Subscribe
More
  • Home
  • The Science of RadioGel®
  • Press Releases
  • PRnT™
  • IDE Submission
  • Research Papers
  • RadioGel® Cancer Blog
  • RadioGel® T-Shirt Contest
  • Meet The Team
  • Contact Us
  • Vivos Inc.
  • IsoPet®
  • Subscribe
  • Home
  • The Science of RadioGel®
  • Press Releases
  • PRnT™
  • IDE Submission
  • Research Papers
  • RadioGel® Cancer Blog
  • RadioGel® T-Shirt Contest
  • Meet The Team
  • Contact Us
  • Vivos Inc.
  • IsoPet®
  • Subscribe

We are currently accepting inquiries for our human clinical trials in India.

We are currently accepting inquiries for our human clinical trials in India.

We are currently accepting inquiries for our human clinical trials in India.

We are currently accepting inquiries for our human clinical trials in India.

We are currently accepting inquiries for our human clinical trials in India.

We are currently accepting inquiries for our human clinical trials in India.

Welcome to RadioGel®

RadioGel® is a division of Vivos Inc. 

RadioGel® Human Clinical Trials - India

Please send us a message if you would like more information on participating in clinical trials in Bangalore, India. Applications are open worldwide.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Do you or somone you know have cancer?

We are currently accepting applications for individuals diagnosed with solid cancerous tumors of the head and neck, including those that are inoperable. Applications are open worldwide for anyone who can travel to Bangalore, India


If you are interested in learning more about our clinical trial in Bangalore, India, please reach out to us. A member of our team will contact you to provide further details. 


RadioGel® is currently not approved for use by the FDA for cancer treatment in the USA.


Bangalore, India

An ongoing clinical trial in India is currently evaluating the efficacy of RadioGel® treatment and is accepting international patients who are willing to travel to Bangalore, India. This trial aims to provide innovative treatment options for individuals with solid, non-metastatic tumors. Patients with inoperable tumors may also be eligible for participation.


Eligibility Criteria: 

  • Must have a solid cancerous tumor. 
  • Tumors should not have metastasized. 
  • Patients with inoperable tumors are encouraged to apply


Bangalore, India, is a leading hub for medical advancements in cancer treatment, driven by cutting-edge research, top-tier hospitals, and advanced technology. The city is home to renowned institutions like Kidwai Memorial Institute of Oncology, HCG Cancer Centre, and Narayana Health, which utilize state-of-the-art robotic surgeries, precision oncology, and AI-driven diagnostics. Bangalore’s biotech ecosystem fosters innovation in personalized medicine, immunotherapy, and genomic research, making it a global destination for advanced cancer care. With strong collaborations between research institutions, startups, and healthcare providers, the city continues to push the boundaries of cancer treatment and patient care.

 Disclaimer: This clinical trial is conducted overseas and is not approved by the U.S. Food and Drug Administration (FDA). Participation is entirely voluntary, and by enrolling, you acknowledge that the treatment protocols may not meet U.S. regulatory standards. Additionally, you will be responsible for all associated costs, including travel, accommodation, and medical expenses. If you choose to proceed, you will be required to sign a waiver confirming your understanding and acceptance of these terms. 

How RadioGel® works!

Our patented Precision Radionuclide Therapy™ is demonstrated in this video detailing how we kill a cancerous tumor from the inside out.


The technology is used in our IsoPet® treatment for small and large animals and for RadioGel® for treating cancer in humans. 


RadioGel® is currently NOT approved by the FDA. Our journey to IDE submission can be viewed with this link.

Revolutionizing Cancer Treatment

The Science Of RadioGel®

Y-90 RadioGel™ is a device designed for radiation treatment of solid tumors. The Y-90 RadioGel™/Hydrogel mixture is injected directly and uniformly into tumors.

Learn More

IDE Submission

 IDE submission marks our first filing with the FDA following the grant of the FDA Breakthrough Device Designation for the RadioGel® Precision Radionuclide Therapy. To read the full press releases click here.  Read the Press Release


RadioGel™ is currently not approved for human use. 

Learn More

Precision Radionuclide Therapy™

Also known as PRnT™, the treatment uses highly localized radiation to destroy cancerous tumors by placing a radioactive isotope directly inside the treatment area, delivering therapeutic radiation from within the tumor. 

Learn More

Meet The Team

We are a team dedicated to developing a safer, less invasive cancer treatment for humans and animals worldwide.

Learn More

The RadioGel® Blog

learn more

Stay Informed

Sign up to have the latest press releases sent directly to your inbox.

Sign Up

Press Releases

Click the link for the latest press releases

Press Releases

Vivos Inc

RadioGel is a division of Vivos Inc.

www.VivosInc.com

Follow us on social for updates.

Copyright © 2025 RadioGel™ - All Rights Reserved.

Powered by

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

DeclineAccept